Grünenthal

Closed portfolio snapshot

According to ClinicalTrials.gov-derived indexes, Grünenthal sits in the top decile of US sponsors by registered trial count (#886 of 15,742 sponsors by registered trial count).

16 total trials none currently recruiting 11 completed top decile by trial count

Grünenthal: 16 sponsored US clinical trials, none currently recruiting.

Grünenthal sponsors 16 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 11 completed. 8 of these trials are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Complex Regional Pain Syndrome, with 1 trials.

Top-decile sponsor footprint

Grünenthal ranks in the top decile of sponsors by registered trial count (#886 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 11/100

11 of 16 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (68.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

16 total, page 1 of 1

COMPLETED Phase 1

A Trial to Investigate Safety and Pharmacokinetics of GRT6019, Including Food Effect, in Healthy Male Participants

NCT07317063

COMPLETED Phase 3

Comparison of a Single RTX-GRT7039 and Placebo Intra-articular Injection for Pain Associated With Osteoarthritis of the Knee

NCT05449132

COMPLETED Phase 3

Open-label Trial to Check the Safety and Tolerability of RTX-GRT7039 Injections for Pain Associated With Osteoarthritis of the Knee

NCT05377489

TERMINATED Phase 3

Efficacy and Safety of Intravenous Neridronic Acid in Complex Regional Pain Syndrome (CRPS)

NCT03560986

TERMINATED Phase 3

Efficacy and Safety of Intravenous Neridronic Acid in CRPS

NCT03530345

COMPLETED Phase 3

Safety of Intravenous Neridronic Acid in CRPS

NCT02972359

COMPLETED Phase 2

Efficacy and Safety of Intravenous Neridronic Acid in CRPS-I

NCT02402530

COMPLETED Phase 3

A Study to Look at Tapentadol Oral Solution in Children and Adolescents in Pain

NCT02081391

TERMINATED Phase 2

Use of Tapentadol Oral Solution for Pain After Surgery in Children From Newborn to Less Than 2 Years Old

NCT02221674

COMPLETED Phase 2

Pharmacokinetic, Efficacy and Safety Study of Tapentadol Oral Solution in Children With Postoperative Pain

NCT01729728

COMPLETED Phase 2

Intravenous Tapentadol in Post-Bunionectomy Pain

NCT01435577

COMPLETED Phase 2

Efficacy and Safety of EN3324 (Axomadol) in Subjects With Chronic Low Back Pain

NCT01043263

TERMINATED Phase 2

A Trial in Painful Diabetic Peripheral Neuropathy With GRT3983Y

NCT01056315

COMPLETED Phase 3

A Trial to Evaluate CG5503 Efficacy and Safety in Acute Pain After Bunionectomy

NCT00609466

TERMINATED Phase 3

A Study to Evaluate the Effectiveness and Safety of CG5503 (Tapentadol) in the Treatment of Chronic Tumor Related Pain Compared With Placebo and Morphine

NCT00505414

COMPLETED Phase 2

Efficacy and Safety of GRT9906 Tablets Compared to Placebo in Patients With Fibromyalgia

NCT03783910

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 7
Phase 3 8

Therapeutic Areas

How the Grünenthal archive is shaped

16 indexed studies, none listed as recruiting (0% open); 11 completed (69%).

Phase mix: 8 late (III/IV) vs 8 early (I/II) (balanced across stages).

Top condition: Complex Regional Pain Syndrome (1 trial), 2 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Grünenthal: archived-pipeline peers nationwide

Peers matched on 16 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Grünenthal sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05101520 0%5%10%15% Total trials Recruiting share GrünenthalAccelerated Community Oncology Research NetworkAltimmuneAmerican UniversityAnthera Pharmaceuticals10xBio22nd Century Group23andMe3-C Institute for Social Development
Grünenthal sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Grünenthal sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 16 archived trials

Sponsors with similar archive density (± trial count)

What to do with this Grünenthal page

16 registered trials is a research-attention snapshot, not an endorsement of Grünenthal or any single study.

  • None of Grünenthal's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Complex Regional Pain Syndrome is the condition Grünenthal studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Complex Regional Pain Syndrome trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Grünenthal pipeline card: 16 registered trials from official public datasets.Report a data error.